Compare SFIX & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | QTTB |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.4M | 450.1M |
| IPO Year | 2017 | 2018 |
| Metric | SFIX | QTTB |
|---|---|---|
| Price | $3.16 | $162.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.5M | 431.8K |
| Earning Date | 06-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.44 | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,226,505,000.00 | $53,737,000.00 |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.52 | N/A |
| 52 Week Low | $2.95 | $1.62 |
| 52 Week High | $5.92 | $23.57 |
| Indicator | SFIX | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 55.57 |
| Support Level | $2.99 | $14.44 |
| Resistance Level | $3.58 | $16.78 |
| Average True Range (ATR) | 0.17 | 0.83 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 9.39 | 62.25 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).